Procter & Gamble (PG) price target to $58 from $60 at Caris
Caris lowered Procter & Gamble's (NYSE: PG) price target following the Rx drug divestiture. The firm is positive on the move long-term but said it is dilutive near-term. Shares are Buy rated.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Downgrades Analyst Ratings